Baocai Xing
- Molecular Biology top 5%
- Oncology top 1%
- Immunology top 2%
- Cancer Research top 2%
- Hepatology top 1%
- Topics
- Hepatocellular Carcinoma Treatment and Prognosis (57 papers)Colorectal Cancer Treatments and Studies (36 papers)Cholangiocarcinoma and Gallbladder Cancer Studies (30 papers)
- Cited by
- HepatologyOncologyImmunology
- Journals
- ScienceCellNucleic Acids Research
- Partner nations
- ChinaEthiopiaUnited States
In The Last Decade
Baocai Xing
117 papers receiving 3.9k citations
Hit Papers
Peers
Comparison fields: 5 of 113
- Molecular Biology 1.7k
- Oncology 1.7k
- Immunology 1.2k
- Cancer Research 825
- Hepatology 766
Countries citing papers authored by Baocai Xing
This map shows the geographic impact of Baocai Xing's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Baocai Xing with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Baocai Xing more than expected).
Fields of papers citing papers by Baocai Xing
This network shows the impact of papers produced by Baocai Xing. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Baocai Xing. The network helps show where Baocai Xing may publish in the future.
Co-authorship network of co-authors of Baocai Xing
This figure shows the co-authorship network connecting the top 25 collaborators of Baocai Xing. A scholar is included among the top collaborators of Baocai Xing based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Baocai Xing. Baocai Xing is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 0 | |
| 2 | 0 | |
| 3 | 10 | |
| 4 | 1 | |
| 5 | 4 | |
| 6 | 14 | |
| 7 | 3 | |
| 8 | 0 | |
| 9 | 35 | |
| 10 | 12 | |
| 11 | Sorafenib Plus Hepatic Arterial Infusion Chemotherapy versus Sorafenib for Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombosis: A Randomized Trialbreakdown → | 101 |
| 12 | Pan-cancer single-cell landscape of tumor-infiltrating T cellsbreakdown → | 699 |
| 13 | 19 | |
| 14 | A pan-cancer single-cell transcriptional atlas of tumor infiltrating myeloid cellsbreakdown → | 820 |
| 15 | 1 | |
| 16 | 23 | |
| 17 | 14 | |
| 18 | 43 | |
| 19 | 80 | |
| 20 | 27 |
About Baocai Xing
Baocai Xing is a scholar working on Hepatology, Oncology and Cancer Research, having authored 124 papers that have together received 3.9k indexed citations. Recurring topics across this work include Hepatocellular Carcinoma Treatment and Prognosis (57 papers), Colorectal Cancer Treatments and Studies (36 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (30 papers). The work is most often cited by research in Hepatology (766 citations), Oncology (1.7k citations) and Immunology (1.2k citations). Baocai Xing has collaborated with scholars based in China, Ethiopia and United States. Frequent co-authors include Zhaode Bu, Xianwen Ren, Zemin Zhang, Ranran Gao, Xueda Hu, Xiaojuan Du, Kun Wang, Chunfeng Zhang, Xiaofeng Liu and Jiafu Ji. Their work appears in journals such as Science, Cell and Nucleic Acids Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.